MRK vs GILD — Key Metrics

Metric MRK (MERCK & CO INC) GILD (GILEAD SCIENCES INC)
Price137.78168.98
Market Cap339.66 Billion209.59 Billion
P/E (TTM)137.78-54.51
P/B (Quarterly)8.25716.235
P/S (TTM)5.046.76
Net Profit Margin (TTM)3.6-12.5
Gross Margin (TTM)71.879.9
ROE (TTM)5.3-21.7
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

MERCK & CO INC
vs
 
GILEAD SCIENCES INC
 
MERCK & CO INC
vs
 
GILEAD SCIENCES INC
Performance Comparison
AI Model Recommendation
MRK · MERCK & CO INC

Greatly Outperform

82
UnderperformOutperform
GILD · GILEAD SCIENCES INC

Outperform

57
UnderperformOutperform
Recommendation Summary

Stock MRK is projected to greatly outperform the market, stock GILD is projected to outperform the market. Upfront Recommendation: MRK.

Financial Metrics
Prices delayed ~15 min
MRK Metrics GILD
$137.78 Price $168.98
— Market Capitalization —
5.04 Price to Sales 6.76
23.03 Price to FCF Ratio 15.21
7.03 Price to Gross Profit 8.46
11.04 Price to R&D 33.12
8.72 Price to Current Assets 12.66

MRK vs GILD at a glance

Merck & CO INC (MRK) and Gilead Sciences INC (GILD) are both Drug Manufacturers - General companies in the Healthcare sector. MRK is the larger, at $339.7 billion in market value against $209.6 billion for GILD, about 1.6 times the size.

On trailing-twelve-month figures, MRK trades at 5.0 times trailing sales and GILD at 6.8; net profit margins are 3.6% and -12.5%.

The Upfront Investment model currently rates MRK Greatly Outperform and GILD Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.